Exelixis Inc (OQ:EXEL)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1851 Harbor Bay Parkway
ALAMEDA CA 94502
Tel: N/A
Website: https://www.exelixis.com
IR: See website
<
Key People
Michael M. Morrissey
President, Chief Executive Officer, Director
Christopher J. Senner
Chief Financial Officer, Executive Vice President
Dana T. Aftab
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Jeffrey J. Hessekiel
Executive Vice President, General Counsel, Secretary
Patrick Joseph Haley
Executive Vice President - Commercial
Amy Peterson
Executive Vice President, Product Development & Medical Affairs and Chief Medical Officer
Peterson C. Peterson
Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
   
Business Overview
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Financial Overview
For the fiscal year ended 29 December 2023, Exelixis Inc revenues increased 14% to $1.83B. Net income increased 14% to $207.8M. Revenues reflect CABOMETYX segment increase of 17% to $1.61B, License revenues segment increase of 10% to $178.6M, U.S segment increase of 16% to $1.65B, Japan segment increase of 37% to $39.5M. Net income also reflects Interest Income increase from $33.1M to $86.5M (income).
Employees: 1,310 as of Dec 29, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $5,824M as of Dec 29, 2023
Annual revenue (TTM): $1,830M as of Dec 29, 2023
EBITDA (TTM): $196.60M as of Dec 29, 2023
Net annual income (TTM): $207.77M as of Dec 29, 2023
Free cash flow (TTM): $292.86M as of Dec 29, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 303,194,259 as of Jan 29, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.